CDT Equity Issues 12.1M Pre-Funded Warrants to Acquire 4.76% of Sarborg, with CEO Participating
CDT is trading near its 52-week low of $2.53 (13% above the low) on light trading volume (0.1× avg).
Summary
CDT Equity is acquiring a 4.76% stake in Sarborg Limited by issuing pre-funded warrants for 12.1 million shares — a massively dilutive transaction that could increase shares outstanding by over 18x. CEO Andrew Regan's entity is receiving 5.4 million of those warrants.
Key Events · M&A and Partnerships · CDT
-
Sarborg Stake Acquired for Warrants
In exchange for pre-funded warrants to purchase 12,131,770 shares of CDT common stock at $0.0001 per share, CDT acquired 270 shares of Sarborg Limited, representing a 4.76% stake, from investors.
-
Massive Potential Dilution
The 12.1 million warrant shares represent approximately 18x the 663,179 shares currently outstanding, though exercise is contingent on stockholder approval and subject to a 19.99% Nasdaq cap until then.
-
CEO Participation
As part of the transaction, CEO Andrew Regan's wholly-owned Corvus Capital Limited received pre-funded warrants for 5,436,830 shares, aligning his interests but also increasing his potential control.
-
Service Provider Share Issuance
Separately, on July 30-31, 2026, CDT issued 123,537 shares to four service providers as compensation for services, adding to the dilution.
Analysis · CDT · Life Sciences
To acquire a 4.76% stake in Sarborg Limited, CDT Equity is issuing pre-funded warrants for 12.1 million shares — roughly 18x its current outstanding share count. The warrants cannot be exercised until stockholder approval is obtained, but the sheer scale of potential dilution is enormous. CEO Andrew Regan, through his Corvus Capital, is receiving warrants for 5.4 million shares, aligning his interests but also concentrating control. Adding to the dilution, the company also issued 123,537 shares to service providers. This transaction comes as CDT faces a cash crisis with only $97,000 on hand and a going concern warning, making the Sarborg stake a high-risk bet with shareholder capital.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $2.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $2.53 to $3,800.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.